Search results
Results From The WOW.Com Content Network
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus , a region of the brain which is known to control appetite. [ 6 ]
Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. [ 11 ] Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC , the main pharmacologically active component ...
Arena Pharmaceuticals (ARNA) announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the ...
Deprescribing can improve adherence, cost, and health outcomes but may have adverse drug withdrawal effects. More specifically, deprescribing is the planned and supervised process of intentionally stopping a medication or reducing its dose to improve the person's health or reduce the risk of adverse side effects .
Science & Tech. Shopping. Sports
Amylyx Pharmaceuticals announced Thursday that it has begun the process of voluntarily withdrawing its ALS drug, Relyvrio, from the market after it failed to prove efficacy in a large clinical trial.
A higher number of cardiovascular events has been observed in people taking sibutramine versus control (11.4% vs. 10.0%). [16] In 2010, the FDA noted the concerns that sibutramine increases the risk of heart attacks and strokes in patients with a history of cardiovascular disease.
Orlistat is used for the treatment of obesity.The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat.